Biotransformation of blood long-chain fatty acids and oxylipins in peripheral tissue during hemodialysis

Background: Cardiovascular disease (CVD) is the most common lethal complications in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). The role of long-chain fatty acids (LCFAs) and their oxylipin derivatives is poorly understood in human cardiac and renal diseases. Based on previous scientific findings, there is evi-dence that many substance profiles of blood LCFAs and their oxylipin derivatives are altered in dialysis patients and influenced by extracorporeal circulation. In order to pro-vide novel insights into biotransformation and/or bioaccumulation of these metabolites in peripheral tissue, we conducted a targeted lipidomic study and tested the hypothesis that arterio–venous (A–V) differences in blood LCFAs and oxylipins are present in vivo and sensitive to single HD treatment. Methods: We took arterial and venous blood samples specimens from ESRD patients (n=12) before and after HD and determined LCFAs and its derived epoxy and hydroxy metabolites in plasma and erythrocytes by high-performance liquid chromatography with mass spectrometry coupling (HPLC-MS). Results: Firstly, we found that the total amount of numerous saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), and polyunsaturated fatty acids (PUFAs) in erythrocytes showed negative arteriovenous (AV) differences before HD, which disappeared after HD. The omega-3 index in erythrocytes did not show arteriove-nous differences before and after HD. No significant findings were observed in LCFAs in plasma. Beyond that, all CYP epoxy metabolites in the plasma showed negative arterio-venous differences, mainly due to their significantly elevated levels in venous blood af-ter dialysis. No changes were observed in LOX and LOX/CYP ω/(ω-1)-hydroxylase me-tabolites in the plasma before and after dialysis. This variation in epoxide metabolites may be attributed to a decrease in soluble epoxide hydrolase (sEH) activity. Conclu-sions: Our findings indicate that AV differences in LCFAs are present and active in ma-ture red blood cells (RBCs) and that their bioaccumulation is susceptible to a single HD therapy [1]. HD treatment changes CYP epoxy metabolites from PUFAs in the plasma (accumulation), which may have deleterious effects on the circulation [2].

Author dc:creator

• Liu, Tong

• eicosanoids
• lipidomics
• oxylipins
• erythrocyte
• arterio-venous

Licence dc:rights.uri

• https://creativecommons.org/licenses/by-nc-nd/4.0/

Language dc:language

eng

Identifier URI

http://dx.doi.org/10.17169/refubium-38782

OAI record oai:identifier

https://refubium.fu-berlin.de/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Arefubium.fu-berlin.de%3Afub188%2F39066